

**Editor**

Josef S Smolen

Associate Editors

Francis Berenbaum
Dimitrios Boumpas
Gerd Burmester
Mary Crow
Iain McInnes
Thomas Pap
David Pisetsky
Desirée van der Heijde
Kazuhiko Yamamoto

Editorial office

Annals of the Rheumatic Diseases
BMJ Publishing Group Ltd
BMA House
Tavistock Square
London WC1H 9JR, UK
T: +44 (0)20 3655 5889
E: ard@bmj.com
Twitter: @ARD_BMJ
ISSN: 0003-4967 (print)
ISSN: 1468-2060 (online)
Impact Factor: 12.350

Disclaimer: ARD is owned and published by BMJ Publishing Group Ltd (a wholly owned subsidiary of the British Medical Association) and the European League Against Rheumatism. The owners grant editorial freedom to the Editor of ARD. ARD follows guidelines on editorial independence produced by the World Association of Medical Editors and the code on good publication practice of the Committee on Publication Ethics.

ARD is intended for medical professionals and is provided without warranty, express or implied. Statements in the journal are the responsibility of their authors and advertisers and not authors' institutions the BMJ Publishing Group, the European League Against Rheumatism or the BMA unless otherwise specified or determined by law. Acceptance of advertising does not imply endorsement.

To the fullest extent permitted by law, the BMJ Publishing Group shall not be liable for any loss, injury or damage resulting from the use of ARD or any information in it whether based on contract, tort, or otherwise. Readers are advised to verify any information they choose to rely on.

Copyright: © 2018 BMJ Publishing Group and European League Against Rheumatism. All rights reserved; no part of this publication may be reproduced stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying recording, or otherwise without prior permission

ARD is published by BMJ Publishing Group Ltd typeset by Exeter Premedia Services Private Ltd, Chennai, India and printed in the UK on acid-free paper.

Annals of the Rheumatic Diseases (ISSN No: 0003-4967) is published monthly by BMJ Publishing Group and distributed in the USA by Air Business Ltd. Periodicals postage paid at Jamaica NY 11431
POSTMASTER: send address changes to *Annals of the Rheumatic Diseases*, Air Business Ltd, c/o Worldnet Shipping Inc., 156-15, 146th Avenue, 2nd Floor, Jamaica, NY 11434, USA.

Editorial

- 1699** Therapeutic innovation in adult-onset Still's disease (and other rare inflammatory disorders): how to secure evidence-based medicine?
P Guilpain, A Le Quellec, A T J Maria

Views on news

- 1702** Extraintestinal translocation of microbes and tissue specificity in rheumatic musculoskeletal disease (RMD): its more than a gut feeling
T R D J Radstake

Clinical and epidemiological research

- 1705** Characteristics of difficult-to-treat rheumatoid arthritis: results of an international survey
N M T Roodenrys, M J H de Hair, M C van der Goes, J W G Jacobs, P M J Welsing, D van der Heijde, D Aletaha, M Dougados, K L Hyrich, I B McInnes, U Mueller-Ladner, L Senolt, Z Szekanecz, J M van Laar, G Nagy, On behalf of the whole EULAR Task Force on development of EULAR recommendations for the comprehensive management of difficult-to-treat rheumatoid arthritis

- 1710** Canakinumab in patients with systemic juvenile idiopathic arthritis and active systemic features: results from the 5-year long-term extension of the phase III pivotal trials
N Ruperto, H I Brunner, P Quartier, T Constantin, N M Wulffraat, G Horneff, O Kasapcopur, R Schneider, J Anton, J Barash, R Berner, F Corona, R Cuttica, M Fouillet-desjonqueres, M Fischbach, H E Foster, D Foell, S C Radominski, A V Ramanan, R Trauzeddel, E Unsal, J Levy, E Vritzali, A Martini, D J Lovell, On behalf of the Paediatric Rheumatology International Trials Organisation (PRINTO) and the Pediatric Rheumatology Collaborative Study Group (PRCSG)

- 1720** Tocilizumab in patients with adult-onset still's disease refractory to glucocorticoid treatment: a randomised, double-blind, placebo-controlled phase III trial
Y Kaneko, H Kameda, K Ikeda, T Ishii, K Murakami, H Takamatsu, Y Tanaka, T Abe, T Takeuchi

- 1730** Reliability of a consensus-based ultrasound definition and scoring for enthesitis in spondyloarthritis and psoriatic arthritis: an OMERACT US initiative
P V Balint, L Terslev, P Aegerter, G A W Bruyn, I Chary-Valckenaere, F Gandjbakhch, A Iagnocco, S Jousse-Joulin, I Möller, E Naredo, W A Schmidt, R J Wakefield, M-A D'Agostino, on behalf of the OMERACT Ultrasound Task Force members

- 1736** Can disease activity in patients with psoriatic arthritis be adequately assessed by a modified Disease Activity index for Psoriatic Arthritis (DAPSA) based on 28 joints?
B Michelsen, J Sexton, J S Smolen, D Aletaha, N S Krogh, D van der Heijde, T K Kvien, M L Hetland

- 1742** Effect of in utero hydroxychloroquine exposure on the development of cutaneous neonatal lupus erythematosus
J Barsalou, N Costedoat-Chalumeau, A Berhanu, C Fors-Nieves, U Shah, P Brown, C A Laskin, N Morel, K Levesque, J P Buyon, E D Silverman, P M Izmirly

- 1750** Incidence, prevalence and treatment burden of polymyalgia rheumatica in the UK over two decades: a population-based study
R J Partington, S Muller, T Helliwell, C D Mallen, A Abdul Sultan

- 1757** Etanercept in patients with inflammatory hand osteoarthritis (EHOA): a multicentre, randomised, double-blind, placebo-controlled trial
M Kloppenburg, R Ramonda, K Bobacz, W-Y Kwok, D Elewaut, T W J Huizinga, F P B Kroon, L Punzi, J S Smolen, B Vander Cruyssen, R Wolterbeek, G Verbruggen, R Wittoek

Basic and translational research

- 1765** Ectopic RASGRP2 (CalDAG-GEFI) expression in rheumatoid synovium contributes to the development of destructive arthritis
H Nakamura, S Shimamura, S Yasuda, M Kono, M Kono, Y Fujieda, M Kato, K Oku, T Bohgaki, T Shimizu, N Iwasaki, T Atsumi

MORE CONTENTS ►



EDITOR'S CHOICE

This article has been chosen by the Editor to be of special interest or importance and is freely available online.



OPEN ACCESS

This article has been made freely available online under the BMJ Journals open access scheme.

See <http://authors.bmj.com/open-access/>



Member since 2008

JMD0004

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics

<http://publicationethics.org/>



When you have finished with this please recycle it

- 1773** Mast cells in early rheumatoid arthritis associate with disease severity and support B cell autoantibody production
F Rivellese, D Mauro, A Nerviani, S Pagani, L Fossati-Jimack, T Messemaker, F A S Kurreeman, R E M Toes, A Ramming, S Rauber, G Schett, G W Jones, S A Jones, F W Rossi, A de Paulis, G Marone, M E M El Shikh, F Humby, C Pitzalis
- 1782** Intrarenal activation of adaptive immune effectors is associated with tubular damage and impaired renal function in lupus nephritis
C Pamfil, Z Makowska, A De Groof, G Tilman, S Babaei, C Galani, P Montigny, N Demoulin, M Jadoul, S Aydın, R Lesche, F McDonald, F A Houssiau, B R Lauwerys
- 1790** Cleaved N-terminal histone tails distinguish between NADPH oxidase (NOX)-dependent and NOX-independent pathways of neutrophil extracellular trap formation
E Pieterse, N Rother, C Yanginlar, J Gerretsen, S Boeltz, L E Munoz, M Herrmann, P Pickkers, L B Hilbrands, J van der Vlag
- 1799** Increased autophagy is cytoprotective against podocyte injury induced by antibody and interferon- α in lupus nephritis
Y Qi, X Zhou, F Cheng, P Hou, Y Ren, S Wang, M Zhao, L Yang, J Martinez, H Zhang
- 1810** Galectin-9 is an easy to measure biomarker for the interferon signature in systemic lupus erythematosus and antiphospholipid syndrome
L L van den Hoogen, J A G van Roon, J S Mertens, J Wienke, A P Lopes, W de Jager, M Rossato, A Pandit, C G K Wichers, F van Wijke, R D E Fritsch-Stork, T R D J Radstake
- 1815** Interleukin 12 and interleukin 23 play key pathogenic roles in inflammatory and proliferative pathways in giant cell arteritis
R Conway, L O'Neill, G M McCarthy, C C Murphy, A Fabre, S Kennedy, D J Veale, S M Wade, U Fearon, E S Molloy
- 1825** Dysregulated neutrophil responses and neutrophil extracellular trap formation and degradation in PAPA syndrome
P Mistry, C Carmona-Rivera, A K Ombrello, P Hoffmann, N L Seto, A Jones, D L Stone, F Naz, P Carlucci, S Dell'Orso, G Gutierrez-Cruz, H-W Sun, D L Kastner, I Akesentijevich, M J Kaplan
- 1836** In RA, becoming seronegative over the first year of treatment does not translate to better chances of drug-free remission
E C de Moel, V F A M Derksen, L A Trouw, H Bang, Y P M Goekoop-Ruiterman, G M Steup-Beekman, T W J Huizinga, C F Allaart, R E M Toes, D van der Woude
- 1838** Short-term and low-dose IL-2 therapy restores the Th17/Treg balance in the peripheral blood of patients with primary Sjögren's syndrome
M Miao, Z Hao, Y Guo, X Zhang, S Zhang, J Luo, X Zhao, C Zhang, X Liu, X Wu, D Xu, J Zhao, X Lu, C Gao, X Li
- 1840** Clinical associations and expression pattern of the autoimmunity susceptibility factor DIORA-1 in patients with primary Sjögren's syndrome
L A Aqrabi, L Mentlein, L Meneghel, A Björk, G E Thorlacius, M Ivanchenko, J I Ramírez Sepúlveda, K Skarstein, M Kvarnström, S Brauner, A Espinosa, M Wahren-Herlenius
- 1842** Increase in circulating cells coexpressing M1 and M2 macrophage surface markers in patients with systemic sclerosis
S Soldano, A C Trombetta, P Contini, V Tomatis, B Ruaro, R Brizzolara, P Montagna, A Sulli, S Paolino, C Pizzorni, V Smith, M Cutolo
- 1845** Association of circulating CXCL10 and CXCL11 with systemic sclerosis
C Crescioli, C Corinaldesi, V Ricciari, V Raparelli, M Vasile, F Del Galdo, G Valesini, A Lenzi, S Basili, C Antinozzi

Electronic pages

- e84** Calprotectin is not independent from baseline erosion in predicting radiological progression in early rheumatoid arthritis. Comment on 'Calprotectin as a marker of inflammation in patients with early rheumatoid arthritis' by Jonsson *et al*
M Chevreau, M-H Paclet, X Romand, J-L Quesada, O Vittecoq, P Dieudé, B Toussaint, P Gaudin, A Baillet
- e85** Response to: 'Calprotectin is not independent from baseline erosion in predicting radiological progression in early rheumatoid arthritis' by Chevreau *et al*
M K Jonsson, N P Sundlisæter, H H Nordal, H B Hammer, A-B Aga, D van der Heijde, T K Kvien, B-T S Fevang, S Lillegraven, E A Haavardsholm
- e86** Simultaneous inhibition of $\alpha 4/\beta 7$ integrin and tumour necrosis factor- α in concomitant spondyloarthritis and inflammatory bowel disease
N Richard, E M Hazel, N Haroon, R D Inman

Letters

- 1835** Frequency of tumour necrosis factor alpha receptor superfamily 1A multiple sclerosis-associated variants in patients with rheumatoid arthritis with anti-tumour necrosis factor therapy-related demyelinating complications
S Bitoun, C Miceli-Richard, C Verstuyft, P A Juge, P Dieudé, J-M Berthelot, C Richez, C Cauquil, C Sordet, S Melac-Ducamp, L Gossec, B Bouvard, E Dernis, E Houvenagel, M-A Boutry-Bacle, X Mariette, R Seror

- e87** Response to: 'Simultaneous inhibition of $\alpha 4/\beta 7$ integrin and tumor necrosis factor- α in concomitant spondyloarthritis and inflammatory bowel disease' by Richard *et al*
G Varkas, D Elewaut
- e88** Standard dose of Ustekinumab for childhood-onset deficiency of interleukin-36 receptor antagonist
B Cherqaoui, L Rossi-Semerano, M Piram, I Koné-Paut
- e89** Response to: 'Standard dose of ustekinumab for childhood-onset deficiency of interleukin-36 receptor antagonist' by Cherqaoui *et al*
N Bonekamp, R Caorsi, J Frenkel, M Gattorno
- e90** Performance of the 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies in clinical practice
A Hočevvar, Z Rotar, M Krosel, S Čučnik, M Tomšič
- e91** Response to: 'Performance of the 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies in clinical practice' by Hočevvar *et al*
I E Lundberg, M Bottai, A Tjärnlund